Finerenone and Cardiac Remodeling in HFpEF

Sponsor
Assiut University
Study ID
NCT07830940
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Finerenone — DRUG
    Non-steroidal mineralocorticoid receptor antagonist 10 to 20 mg orally once daily for 6 months with monitoring of potassium creatinine and eGFR
  • Standard of care for HFpEF Description: — OTHER
    Standard of care for heart failure with preserved ejection fraction according to 2022 AHA ACC HFSA guideline including diuretics and guideline-directed medical therapy without Finerenone

Study Details

This prospective randomized study aims to evaluate the efficacy of Finerenone as add-on therapy to standard of care compared to standard of care alone in preventing heart failure worsening and preserving cardiac function assessed by left ventricular strain in patients with heart failure with preserved ejection fraction.

Key Dates

First listed
Sep 21, 2026
Start date
Sep 20, 2026
Status verified
Sep 2026
Primary completion
Sep 25, 2027
Completion
Mar 25, 2028

Study Design

Enrollment
194 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Finerenone plus Standard of Care
    Finerenone 10 mg once daily titrated to 20 mg once daily based on serum potassium and eGFR plus standard of care for HFpEF for 6 months
  • Active Comparator: Standard of Care alone
    Standard of care for HFpEF according to 2022 AHA ACC HFSA guideline without Finerenone

Primary Outcome Measure

Change in left ventricular global longitudinal strain [ Time Frame: From baseline to 6 months ]

Central Contacts

Find similar trials

Nationwide
Heart failure trialsCardiology trialsHeart disease trials

Related Studies